Insulin NPH (Isophane)
Brand names: Humulin I, Insulatard
Insulin NPH (isophane) is an intermediate-acting human insulin suspension used to provide basal insulin cover in type 1 and type 2 diabetes.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It acts on insulin receptors to increase glucose uptake and reduce hepatic glucose production; complexing with protamine forms a crystalline suspension that delays absorption, giving an intermediate duration with a defined peak.
Prescribing in practice
- As a suspension with a pronounced peak, NPH carries a notable risk of hypoglycaemia, particularly overnight.
- Resuspend gently by rolling the cloudy vial or pen before each injection to ensure a uniform, accurate dose.
- Rotate injection sites and review timing, as the peak action can be mistimed relative to meals or sleep.
Monitoring
Monitor capillary blood glucose, including overnight or pre-breakfast values, and HbA1c to guide titration.
Counselling the patient
- Gently mix the cloudy insulin until evenly milky before each dose.
- Carry fast-acting glucose and be especially alert to night-time hypoglycaemia.
- Rotate injection sites and never share pens or needles.
Evidence & guidelines
Isophane (NPH) insulin is a long-standing basal insulin option referenced in NICE diabetes guidance.
Reference: NICE NG3 (Diabetes in Pregnancy); NICE NG17 (Type 1 DM); MHRA Insulin Safety Alert; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016